Otsuka Holdings’ Pharmaceutical Sales Rise 14.8%, Global Sales for Abilify Up 21.9% in April-June Period

August 12, 2013
Otsuka Holdings’ pharmaceutical sales in the April-June period in 2013 rose 14.8% from the same period last year to 224,113 million yen, driven by growing sales of its mainstay antipsychotic Abilify (aripiprazole), the company said on August 8. Its operating...read more